BB Biotech combines a 9.9% NAV discount, strong Q2 outperformance, structural biotech M&A demand, and a probability-weighted 5-year value of CHF 63.31.
Overview
BB Biotech AG is a Swiss-incorporated closed-end investment company established in November 1993 that gives retail and institutional investors liquid, dividend-paying exposure to global biotechnology without requiring them to evaluate complex clinical and regulatory risks directly. It owns no therapeutic products; returns come from portfolio appreciation, realized gains, dividends, and M&A exits. As of mid-2026, the company reported trailing twelve-month revenues of USD 1.75 billion, approximately USD 3.82 billion of total assets, and no long-term debt. **Q2 2026 marked a sharp recovery:** net profit was CHF 451 million versus a CHF 100 million loss in Q2 2025, while NAV total return was 17.2% in CHF, 3.5 percentage points ahead of the NBI. Eight holdings were acquired during the prior six quarters, validating selection and benefiting from big pharma’s need to replace more than USD 250 billion of revenues exposed to patent expiry through 2030. Shares traded at CHF 55.10 against NAV per share of CHF 55.95 in the scenario starting point and later at a 9.9% discount to NAV, with a CHF 61.34 one-year consensus target and Kepler target of CHF 73.00. Near-term catalysts include Phase III readouts, further sector M&A, discount narrowing, and the new 3%–5% dividend policy beginning with the spring 2027 distribution.